Drug Profile
AG 858
Alternative Names: HSPPC-70-CLatest Information Update: 04 Jul 2007
Price :
$50
*
At a glance
- Originator Antigenics
- Class
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Chronic myeloid leukaemia
Most Recent Events
- 19 Jan 2006 Data presented at the 47th Annual Meeting and Exposition of the American Society of Hematology (ASH-2005) have been added to the adverse events and Cancer therapeutic trials sections
- 02 Nov 2005 Antigenics has expanded enrolment in a phase II trial for chronic myeloid leukaemia in the US and UK
- 12 Dec 2003 Data from a media release have been added to the Cancer therapeutic trials section